AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people familiar with the matter, highlighting growing interest in a controversial ...

This clinical study update could influence AbbVie’s stock performance by showcasing its commitment to innovative cancer treatments. Positive outcomes may enhance investor confidence and position ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...